The Squalestatins: Inhibitors of Squalene Synthase. Enzyme Inhibitory Activities and in Vivo Evaluation of C3-Modified Analogues

Citations Over TimeTop 21% of 1996 papers

Abstract

Squalestatin analogues modified in the C1 side chain were prepared and evaluated for their ability to inhibit rat liver microsomal and Candida squalene synthase (SQS) in vitro. While maintaining the 4,6-dimethyloctenoate or 4,6-dimethyloctanoate ester groups at C6, a number of modifications to the C1 side chain were well tolerated. However, in the absence of the C6 ester group, similar modifications to the C1 side chain caused substantial loss of activity. Compounds were also evaluated for their ability to inhibit cholesterol biosynthesis in vivo in rats and to reduce serum cholesterol levels in marmosets. These studies revealed that compounds with similar SQS inhibitory activities can possess different in vivo durations of action and lipid-lowering abilities.

Related Papers

• → Identification of unique mechanisms for triterpene biosynthesis in Botryococcus braunii(2011)157 cited
• → Squalene epoxidase as hypocholesterolemic drug target revisited(2002)186 cited
• → Enhancement of squalene synthesis in Candida tropicalis via combinatorial metabolic engineering strategies to rebuild pathways(2024)8 cited
• → Depletion of the Squalene Synthase ( ERG9 ) Gene Does Not Impair Growth of Candida glabrata in Mice(2000)53 cited
• → Selective Inhibition of Cholesterol Biosynthesis in Brain Cells by Squalestatin 1(1995)22 cited